Abstract 5F11, a fully human monoclonal antibody directed against CD30 effectively induces killing of CD30-expressing lymphoma cell lines in vitro and in animal models. A recently conducted phase I/II study shows that 5F11 is well tolerated in heavily pretreated patients with relapsed and refractory CD30-positive lymphoma and has some clinical activity.
Abstract 5F11, a fully human monoclonal antibody directed against CD30 effectively induces killing of CD30-expressing lymphoma cell lines in vitro and in animal models. A recently conducted phase I/II study shows that 5F11 is well tolerated in heavily pretreated patients with relapsed and refractory CD30-positive lymphoma and has some clinical activity.
In the present study we demonstrate that 5F11 activates NF-kB and the antiapoptotic protein c-flip in HD (Hodgkin's lymphoma)-derived cell lines, which might cause apoptosis resistance thus limiting its clinical use. To overcome this resistance we combined 5F11 with the proteasome inhibitor bortezomib which has been shown to suppress NF-kB activity. This combination revealed a synergistic cytotoxic effect in vitro and in a human HD xenograft model provided that 5F11 precedes bortezomib treatment. We conclude that initial 5F11-mediated NF-kB signaling sensitizes the tumor cells to bortezomib-induced cell death. These data suggest a therapeutic value of this combination for HD patients.
Introduction
The CD30 receptor, a member of the tumor necrosis factor superfamily, is selectively overexpressed in the malignant cell population of Hodgkin's lymphoma (HD) and anaplastic large-cell lymphoma (ALCL) rendering this antigen an excellent target for antibody-based immunotherapy. However CD30 signaling is pleiotropic since antibody binding may induce cell death in ALCL cells, whereas some CD30-positive HD cells respond with growth stimulation [1] [2] [3] . Recently two monoclonal antibodies, the human 5F11 4 and the humanized SGN-30 5 exhibited cytotoxicity against HDderived cell lines as well as against ALCL cells, even though limitations in the sensitivity of HD-target cells were observed. Resistance against apoptosis upon CD30 stimulation might be due to the activation of the survival factor NF-kB, a key anti-apoptosis factor in HD [6] [7] [8] . We found that CD30 stimulation via CD30 activates NF-kB and its target c-flip, which can be inhibited with bortezomib, a proteasome inhibitor known to suppress NF-kB activation. Combination of 5F11 and bortezomib results in cytotoxic synergy both in vitro and in vivo and we conclude that down regulation of NF-kB through bortezomib may be a therapeutic approach to improve CD30 based immunotherapy.
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Material and Methods

Cell lines, antibodies, reagents and plasmids
The Hodgkin-derived cell lines (L540 and L428), the ALCL-line Karpas 299 and the CD30-negative acute lymphoblastic leukemia-line REH were described previously 9 .
The anti-CD30 
XTT-Assay
The XTT assay was performed as described, 4, 9 . Cells were preincubated at 37°C for 30 minutes with 5µg/ml anti-CD30 antibody 5F11 + 25µg/ml goat-anti-human (GaHIgG) and exposed to increasing concentrations of bortezomib for 48 hours.
Luciferase reporter gene assay
Transfected L428 cells (electroporation efficacy 5-10 %) were incubated either with 5µg/ml 5F11+ 25µg/ml GaH for 2 hours, or with 50 ng/ml bortezomib or both or plain medium for 24h at 37°C. Luciferase activity was measured as recommended by Promega, USA.
Electrophoretic mobility shift assay
The nuclear protein extracts (20 mM HEPES, pH 7.9, 400 mM NaCl, 1mM EDTA, 1mM EGTA) derived from cells treated with different antibodies were incubated with 32 P-labeled NF-kB binding site oligonucleotides (Santa Cruz) for 30 minutes at room temperature before electrophoresis on 6 % native polyacrylamide gels.
Xenograft model of human HD
The xenograft model of human HD was described previously 4 . SCID mice with established tumors of about 100mm 3 were divided randomly into four groups and received 100 µg 5F11 (in 200 µL PBS intraperitoneally) and 6 hours later 10 ng bortezomib via the tail vein or each agent alone once weekly for a total of 4 injections. Control mice received PBS only. The experiment was stopped and mice were sacrifized when the median tumor diameter in the control group exceeded 2500 mm 3 (day 50). Two independent experiments were performed. These data provide evidence that resistance to CD30-mediated cell death in HD cells is due to activation of NF-kB.
Combination of 5F11 and bortezomib increases the cytotoxicity against HDand ALCL-derived cell lines
We subsequently evaluated the cytotoxic potential of 5F11 to overcome apoptosis resistance when combined with bortezomib in XTT viability assays.
The cell lines tested were sensitive to bortezomib (IC50, 15 ng/ml for L540 cells, 10 ng/ml for Karpas299, 75 ng/ml for L428 cells). Fig. 2A 
-D presents cell survival upon
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and Karpas 299 and interestingly also for L428 cells, which are resistant to 5F11 even at higher antibody concentrations 4 . No effect was seen with the lymphoblastic leukemia line REH lacking CD30 expression. The pre-incubation with 5F11 is essential for this synergy since pre-incubation with bortezomib for 30 minutes prior antibody addition had no effect (shown for L428). A similar mechanism was recently reported for leukemic stem cells pretreated with NF-kB-activating anthracyclines before exposure to the proteasomes inhibitor MG132 15 . The growth inhibition was maintained for several weeks after treatment, whereas animals receiving either 5F11 or bortezomib alone showed tumor progression.
In vivo activity of 5F11 and bortezomib in a human
In conclusion, down regulation of NF-kB through bortezomib after CD30 mediated NF-kB activation may become a therapeutic approach to improve immunotherapy using monoclonal antibodies against the CD30 antigen. These findings are supported by recently published data showing that bortezomib induces cell death irrespective of NF-kB inhibitor mutations frequently observed in HD-derived cells 18 . Although bortezomib has significant single-agent activity in patients with multiple myeloma and mantle cell lymphoma 19 the efficacy in HD patients is less clear. Currently, there are only few patients reported although the responses seem less impressive 21, 22 . The German Hodgkin Study Group is currently evaluating a combination of bortezomib and dexamethasone in relapsed HD patients. Depending on the outcome of this phase-II-trial the preclinical data presented provide a rationale for a clinical study combining bortezomib/dexamethasone with an anti-CD30 monoclonal antibody. experiments is shown and the standard error mean is given.
(G) Statistical analysis of the tumor volumes measured on day 47 (see F, and an independent serie, each group with n=4). The differences between 5F11, bortezomib and the combination versus the control are significant (the P values are estimated with the paired t-test using GraphPadPrism software).
